NEWS RELEASE

For release: April 14th, 2010
Contacts: Terry Lall, 416-218-5578, tcalinc@rogers.com
Jon Siegal / Jessica Anderson, 781-684-0770, hybridyne@schwartz-pr.com
Diane Greenberg, 631-344-2347, greenb@bnl.gov

Hybridyne Imaging Technologies Receives FDA Clearance for New Medical
Imaging System

Toronto, Ontario-based Medical Imaging Company Releases New Camera for
Diagnosis of Cancer

April 14th, 2010 | Toronto, Ontario – Hybridyne Imaging Technologies, Inc., a
developer of compact, high-resolution gamma cameras for the detection of cancer and
other abnormalities in the body, announces FDA clearance of ProxiScan™
The system can be used in imaging the distribution of radionuclides in the human body using planar
imaging techniques. ProxiScan™ may also be used intra-operatively, on pathological
specimens and for endocavity applications if a protective sheath is used. Terry Lall,
Hybridyne's President and CEO proudly said, “ProxiScan™ is the first gamma camera to
receive FDA clearance for endocavity imaging.”

The unique component of the technology is a small cadmium zinc telluride (CZT)-based
compact gamma camera developed by Hybridyne in collaboration with scientists at
Brookhaven National Laboratory. “The compact size of the instrument allows placement
of the camera close to the objects of interest, thus creating the possibility of reductions in
the radiation dose to patients,” said co-developer Dr. Yonggang Cui of Brookhaven.

ProxiScan™ is also capable of high-performance imaging of radiopharmaceuticals
distributed within anatomical regions of interest located close to the camera head.
“Brookhaven’s pre-clinical laboratory experiments demonstrated the high-spatialresolution and high-contrast capabilities of the instrument. Images of shaped phantoms have shown spatial resolutions as low as 1-2 millimeters, potentially allowing more precise information about the distribution of radionuclides in nuclear medical

Click here to download complete Press Release